Caris Life Sciences (CAI) Q3 2026 earnings review
Caris Life Sciences raises its sales plan, but cash burns
Caris Life Sciences, the cancer-testing group, grew its test volumes faster, but launch spending hurt profit and burned cash. Third-quarter revenue rose 27% to $275 million as clinical cases climbed 21%, and chief executive David Dean Halbert raised the full-year sales outlook. By our math, the new plan points to a 1% fourth-quarter revenue dip only because last year included a large one-time collection catch-up.
| Revenue | $275.4M +27% from a year ago |
|---|---|
| Clinical cases completed | ~61,500 +21% from a year ago |
| Free cash flow | -$39.7M +$55.3M a year ago |
| Full-year revenue outlook | Raised $10M middle of the range: 28.7% growth |
⚖️ Verdict: ⚪ Neutral
The story is unchanged because rising core test orders are offset by heavy upfront spending on unproven consumer launches. Case growth sped up for a second quarter, proving the expanded sales team can drive demand as last year's insurance price hikes fade. The bad news: operating expenses rose 42% and lab supplies more than doubled this year to $138 million, pushing nine-month free cash flow below zero without any disclosed sales from the new Caris Detect early-detection test.
The question now is whether the inventory build and celebrity ad blitz for Caris Detect will turn into paying customers or end up as idle lab capacity. Either doctors and consumers start ordering the self-pay blood test in visible numbers, or the extra fixed costs and supplies drag down margins. Fourth-quarter cash flow and the first disclosed Detect order numbers will tell.
🐂 Bull Case
Test Volume Picked Up as Repricing Faded
"This was another record quarter, with approximately 61,500 clinical cases, up 21% year over year," chief executive David Dean Halbert said. For the past year, higher insurance payment rates drove most of Caris Life Sciences' revenue growth. As the cancer-testing company laps those price increases, growth has to come from doctors ordering more tests.
That handoff is working. Clinical case growth sped up for a second straight quarter, rising from 15.3% in the first quarter and 18.3% in the second to 21.2% in the third. Total revenue rose 27% to $275.4 million, and the Texas group raised its full-year sales plan by $10 million to $1.04–$1.05 billion.
By our math, the new full-year plan points to fourth-quarter revenue of about $290 million, down 1.1% from a year ago. That drop is an accounting quirk because the fourth quarter of 2025 included an $89.8 million catch-up payment from older tests. Excluding that one-off, the plan implies 42.7% underlying fourth-quarter growth and 24.6% case volume growth.
What to watch: fourth-quarter clinical cases against the 65,660 needed by our math to hit the 20% full-year volume plan. Reaching that level without one-off catch-up payments would prove the expanded sales force can carry growth in 2027.
New Launches Expand Blood and Monitoring Reach
Caris built its business on matching cancer patients to drugs at diagnosis. Now Halbert wants to test patients repeatedly during treatment. "Caris Assure® is now available for therapeutic response monitoring, and Caris Confirm, our Whole Genome, tumor-informed assay for minimal residual disease, is targeted to launch before year-end," he said.
During the quarter, the company launched two upgrades to Caris Assure, its blood-based genetic test. One upgrade deepens genetic reading for choosing a drug, while the other extends the test "from therapy selection to serial monitoring of treatment response". It also published a study showing its Caris AI Insights software can predict whether first-line pancreatic cancer treatment will work.
These launches matter because monitoring a patient over time creates multiple test orders per patient instead of just one. Furthermore, targeting Caris Confirm (a test that checks if tiny amounts of cancer remain after treatment) before year-end fulfills management's promise to launch in the second half of 2026.
What to watch: CarisAssure blood test volume and Medicare coverage updates for Caris Confirm in the fourth-quarter report. Rising blood test orders would show doctors are using the platform for repeat monitoring.
🐻 Bear Case
Launch Spending Cut Margin and Burned Cash
Caris is spending heavily to turn Caris Detect, its blood test for finding early-stage cancer in healthy people, into a consumer brand. The company aired two national advertising campaigns with Kevin Costner and Jordan Spieth "spotlighting the importance of early-stage cancer detection and introducing Caris Detect™ to a consumer audience". Management says the test will drive its next wave of growth.
The bill arrived before any disclosed sales. Operating expenses jumped 41.9% from a year ago to $163.0 million, driven by "headcount-related costs, increased research and development investment, and marketing expenditures". Meanwhile, lab supplies inventory rose another $14.6 million from last quarter to $138.4 million, more than double its level at the end of 2025.
- Selling and marketing expense: 21.7% of revenue, up 2.7 percentage points from a year ago
- Research and development expense: 12.3% of revenue, up 2.3 percentage points
- General and administrative expense: 25.2% of revenue, up 1.2 percentage points
- Operating margin: 7.0%, down 8.0 percentage points from 15.1% a year ago
- Free cash flow: negative $39.7 million, down from positive $55.3 million a year ago
Because of the inventory build and ad blitz, nine-month free cash flow turned negative at $10.8 million, missing management's call for break-even cash flow through September. The release omitted any order or revenue numbers for Caris Detect, and it did not repeat the prior full-year targets for operating expenses or positive free cash flow.
What to watch: fourth-quarter free cash flow and the first disclosed order count for Caris Detect. Another quarter of silence on test uptake alongside rising supplies would mean the consumer push is tying up cash without bringing in buyers.
Drug Research Sales Still Trail the Plan
Caris sells research services and genetic data to drugmakers alongside its clinical tests for patients. Earlier this year, management set a full-year target of $75–$85 million for this pharmaceutical division and said sales would cluster in the fourth quarter.
Third-quarter pharmaceutical revenue rose 36.8% from a year ago to $12.7 million, up only $1.2 million from the second quarter. That brings nine-month sales to $29.5 million, down 14.7% from the first nine months of 2025. By our math, hitting the middle of the $75–$85 million annual target would require $50.5 million in the fourth quarter alone — four times the third-quarter level and more than the division made in all of 2025.
The company did not mention the pharmaceutical revenue target in this release, while raising total company revenue guidance. That means patient testing is carrying the entire full-year outlook.
What to watch: fourth-quarter pharmaceutical research revenue against the $50.5 million needed by our math to meet the original plan. A shortfall would confirm that drugmaker contract timing remains too lumpy to anchor annual forecasts.
Risks this quarter didn't answer
Four standing concerns could not be checked in the earnings release and wait for the conference call or quarterly filing.
- Prior-period collection true-ups: the release gave reported revenue per case of $4,272 by our math, but the quarterly filing's footnotes must show how much came from collecting on older tests versus current base prices.
- Tissue versus blood test mix: the release gave only combined clinical cases (~61,500), leaving the volume split between MI Profile (tissue) and Caris Assure (blood) to the filing.
- Medicare 2027 rate update: management expected a federal pricing update in September under the Protecting Access to Medicare Act (PAMA), which was not mentioned in the release.
- Tumor-naive recurrence test: the release updated the tumor-informed Caris Confirm test, but gave no timeline on the separate tumor-naive colon cancer submission to Medicare.
👓 Other Themes
Share Repurchases Continued Alongside Lab Build-Out
Caris kept buying back its own stock even as cash flow turned negative during the quarter. By our math, the company spent $10.0 million on share repurchases in the third quarter, bringing nine-month buybacks to $31.4 million and leaving $72.1 million under its $100 million board authorization. Total cash and marketable securities ended September at $767.4 million against $393.3 million of debt.
💲 Other KPIs
Uncollected customer bills rose 14.1% from last quarter, more than three times the 4.4% sequential increase in revenue. Since the end of 2025, receivables have grown $21.2 million, tying up working capital alongside the laboratory inventory build.
Spending on lab equipment and software was 6.3% of revenue, down from $22.1 million (8.4% of revenue) in the second quarter but more than double the $7.1 million spent a year ago. Nine-month capital spending reached $49.9 million as the group expands sequencing capacity for new tests.
The cumulative database of patient genetic profiles grew by about 70,000 during the quarter, up from 60,000 added in the second quarter. However, matched profiles (which link genetic data to patient clinical outcomes) stayed at 845,000, unchanged from June.
🔮 Guidance
Raised. The middle of the full-year outlook moved up $10 million to $1.045 billion, or 28% to 29% growth, following a $25 million raise last quarter. By our math, that leaves $289.8 million for the fourth quarter (down 1.1% from a year ago, or up 42.7% excluding last year's $89.8 million catch-up payment).
Unchanged. Caris kept its target of roughly 20% full-year case growth over 2025's 199,300 cases. By our math, after completing 173,500 cases in the first nine months, the plan leaves about 65,660 cases for the fourth quarter — up 24.6% from a year ago and 6.8% above the third quarter.
❓ Key Questions
How many Caris Detect tests have customers ordered since launch?
Supplies inventory has more than doubled this year to $138.4 million and national television ads are running, but the release gave no order or revenue numbers for the $3,500 early-detection test.
Does management still expect positive full-year free cash flow?
The third-quarter cash outflow of $39.7 million pushed nine-month free cash flow to negative $10.8 million, and the release omitted the company's earlier full-year cash flow and operating expense targets.
How much of third-quarter revenue came from prior-period collections?
By our math, reported molecular profiling revenue per case was $4,272 against a $3,800–$3,900 base target. Knowing the catch-up collection amount is essential to check whether underlying test prices held firm.
Is the $75–$85 million pharmaceutical revenue target still intact?
Nine-month drug research revenue is $29.5 million, meaning the fourth quarter would have to deliver $50.5 million by our math — four times the third-quarter run rate — to reach the middle of the prior plan.